![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
The present Industry Update covers the period 16 July–15 August 2011, with information sourced from company press releases, media newswires, regulatory agencies and relevant patent offices. The restructuring announced by Merck was not unexpected but its adverse effects will be keenly felt by employees, particularly in the USA. The approval of Pradaxa™ in Europe is welcome and likely to provide a significant clinical benefit. Reports of Phase III clinical studies were few in number, however some exciting early stage research was reported, most notably in relation to the potential development of broad-spectrum antiviral therapeutics.
Financial & competing interests disclosure
Gareth Rees is employed by Genesis Oral Biosciences and has, in the past, received compensation from GlaxoSmithKline in respect of consultancy and scientific writing services. Gareth Rees is a named inventor on four patents assigned to GlaxoSmithKline, and owns shares in the company. Alex Latham is an intern at Genesis Oral Bioscience. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.